Lawrence 2005.

Methods	CPCRA 064 trial N=274 Randomized Open Fup= 36 months
Participants	Eligibility:‐ HIV infection >13 yrs,HIV RNA >5,000 copies/ml, MDR virus, stable ART regime, STI N= 138 STI median age 45 years 8.7 Baseline CD4 153 cells/mm3 Baseline VL 5.0 log copies/ml, ART: 2.2 NNRTI +2.5PI+1.0NNRTI Mut: 10.8
Interventions	4 month STI
Outcomes	Differences in CD4 between STI and control groups:‐ 0‐4 months= 84 cells 5‐24 months =47.0 cells 24 months =42.8 cells STI arm: Loss of all mutations in 26% participants Loss of half mutations in 55% participants. Disease progression events: STI arm: 91 events Control arm: 71 events Deaths: STI arm 30 events Control arm 33 events Quality of life: no differences in both arms Adherence: no differences in both arms.
Notes	No benefit of STI
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate